Glycoprotein D adjuvant herpes simplex virus vaccine (Q36284536)

13 August 2017

1 reference

title

Glycoprotein D adjuvant herpes simplex virus vaccine (English)

1 reference

13 August 2017

David Bernstein

1

1 reference

13 August 2017

publication date

1 October 2005

1 reference

Expert Review of Vaccines

13 August 2017

published in

1 reference

13 August 2017

volume

4

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

615-627

1 reference

Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Neonatal herpes: what have we learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Recent progress in herpes simplex virus immunobiology and vaccine research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Oral transgene vaccination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Herpes Simplex Virus Type-1 Glycoprotein D Gene: Nucleotide Sequence and Expression inEscherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Herpes simplex virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

A gender gap in autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Gender influences herpes simplex virus type 1 infection in normal and gamma interferon-mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Prospects for control of herpes simplex virus disease through immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Why do we lack an effective vaccine against herpes simplex virus infections?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

The potential epidemiological impact of a genital herpes vaccine for women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.5.615

21 January 2018

Identifiers

DOI

10.1586/14760584.4.5.615

1 reference

13 August 2017

1 reference